Transcriptomic Assessment Service for Cancer Signaling Pathway
Creative Biolabs transcends static genomics by quantifying dynamic pathway flux across canonical cascades like PI3K/Akt/mTOR and MAPK/ERK. We decipher drug mechanisms of action (MoA) for novel therapies, including DNA damage response (DDR) inhibitors, by mapping downstream transcriptional fingerprints and metabolic DNA repair modulation. Our platform identifies predictive biomarkers for therapeutic response while detecting emergent bypass signaling in "persister" cells. This functional insight enables the discovery of synergistic combinations and robust roadmaps to overcome therapeutic escape in complex oncology models.
The Vital Role of Transcriptomics in Modern Drug Discovery
Transcriptomics serves as the essential bridge between static genetic information and the dynamic functional behavior of cancer cells. While DNA sequencing identifies potential mutations, transcriptomic assessment reveals the actual execution of those instructions, capturing nuances of pathway crosstalk, epigenetic regulation, and microenvironmental influences. Recent research highlights the necessity of capturing dynamic mRNA signatures to understand complex mechanisms like metabolic cell death and therapeutic response. Creative Biolabs leverages these insights to offer specialized assessments of pathways, including Notch/Wnt signaling and emerging metabolic signatures like cuproptosis.
Comprehensive Transcriptomic Solutions
To empower your drug discovery pipeline, Creative Biolabs offers a diverse suite of specialized assessments designed to capture every facet of oncogenic signaling. Our portfolio includes high-resolution options:
Whole Transcriptome Sequencing
Our high-depth sequencing captures coding and non-coding RNA, identifying novel splicing variants and regulatory elements that drive oncogenic signaling, providing a complete blueprint of the cellular transcriptional landscape.
Signature-Based Pathway Profiling
This module transforms raw expression data into normalized activation scores for critical axes, enabling precise quantification of signaling flux across over 50 specific hallmarks.
Metabolic Cell Death Mapping
We quantify signatures of non-apoptotic pathways, including cuproptosis and ferroptosis. Our pipeline tracks mitochondrial dysfunction and metal-induced signaling to evaluate your compound's impact on emerging cell death mechanisms.
Tumor Microenvironment Deconvolution
This service utilizes advanced algorithms to quantify immune infiltration from bulk RNA-seq data, revealing the complex interplay between signaling drivers and surrounding tumor-associated immune cell populations.
Unlock the Full Potential of Your Research - Connect with an Expert to Get Started
Workflow
Our streamlined process is designed for maximum clarity and scientific rigor, ensuring your data is ready for publication or internal decision-making.
Publication
This study integrates proteomic and transcriptomic data from over 10,000 samples across 13 cancer types to identify pan-cancer dysregulated pathways (e.g., splicing, interferon response) and genes. RRM2 and ADH1B emerge as robust diagnostic biomarkers. The authors also establish TNM stage-based classification models and prognostic risk stratification tools, along with drug predictions targeting CDK, HDAC, and PI3K, offering valuable web-based resources for precision oncology.
Fig.1 A compendium of transcriptomic and proteomic data sets. 1
Why Choose Us?
Creative Biolabs combines two decades of oncology expertise with cutting-edge computational tools to transform sequencing data into biological intelligence. Unlike facilities providing mere lists of differentially expressed genes, our approach focuses on the entire signaling axis. We utilize proprietary signature-based analysis to quantify pathway flux with superior sensitivity, identifying subtle shifts in developmental signaling or metabolic states that others miss. By integrating cross-platform validation and high-resolution bioinformatics, we ensure results are robust for high-impact research. Our dedicated team provides personalized consultation to align pipelines with your experimental goals, whether screening lead compounds or investigating therapeutic escape.
Harness the Creative Biolabs Advantage - Connect with Us for a Detailed Quote Today
FAQs
Can you perform transcriptomic assessment on degraded FFPE samples?
Absolutely. Creative Biolabs utilizes specialized library preparation kits optimized for fragmented RNA from FFPE blocks, ensuring reliable pathway scoring even with lower RIN values typical of archived research specimens.
What is the minimum sample size required for predictive signatures?
While we can analyze individual samples, a cohort of at least 10–15 samples is recommended for statistically significant biomarker discovery and "responder vs. non-responder" modeling using our predictive algorithms.
Are your bioinformatics pipelines compatible with external public datasets?
Yes. We can integrate your proprietary data with public repositories to provide a broader context and validate your findings across larger populations.
Customer Review
-
Exceptional MoA Resolution
Using the pathway assessment service has significantly improved our mapping of DNA repair downregulation following novel treatments. The technical depth of the deconvolution analysis was far beyond what we received from standard core facilities. - Prof. Ma Ri -
Precision in Response Prediction
Using Creative Biolabs' signatures for IFN-γ response elements has significantly facilitated our stratification process. We identified markers of T-cell exhaustion that traditional protein-based assessments completely missed. - Dr. Hy Wg
Related Services
To achieve a comprehensive understanding of the tumor landscape, we recommend combining our pathway assessment with these complementary offerings:
System Immunity Measurement
Creative Biolabs provides gut-brain axis analysis, quantifying cytokine signaling and immunophenotypes. We utilize germ-free models and multi-omics integration to evaluate microbiota-immune cross-regulation in neurological and immunological diseases.
Learn More →Monitoring Host Responses to Gut Microbiota
Creative Biolabs provides host-microbiota interface analysis, quantifying lumenal protein secretion and metabolic profiles. We utilize metatranscriptomics and MS-based proteomics to evaluate gene expression abundance and untargeted metabolome dynamics.
Learn More →How to Contact Creative Biolabs
Creative Biolabs is your strategic partner in deciphering the molecular dialogue of cancer. By providing high-resolution pathway assessment and predictive signatures, we enable the next generation of breakthrough therapies.
Partner with Our Scientific Experts - Connect Today to Discuss Your Custom Project Requirements
Reference
- Hu, G. S., et al. "Integrated Analysis of Proteome and Transcriptome Profiling Reveals Pan-Cancer-Associated Pathways and Molecular Biomarkers." Mol Cell Proteomics 24.3 (2025): 100919. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1016/j.mcpro.2025.100919
Download our brochure